| Literature DB >> 29067226 |
Sabitha Vadakedath1, Venkataramana Kandi2.
Abstract
Chronic renal failure (CRF) is the most prevalent, worldwide public health problem of the elderly population. The main cause of CRF is a damaged kidney. There are five stages of CRF based on the glomerular filtration rate (GFR), and stage 5 (GFR < 15 ml/min/1.73m2) is often called an end-stage renal disease (ESRD). In CRF, there is an accumulation of toxins and excess water due to compromised renal function. Dialysis is the preferred way to treat ESRD and remove accumulated toxins from the body. The cardiovascular risk associated with dialysis is 10 to 20 times higher in patients undergoing dialysis than in normal people. The inflamed kidneys and the process of dialysis also affect endothelial function, aggravating the risk of hypertension and cardiac problems. Therefore, both physicians and patients should be aware of the consequences of undergoing dialysis. There is an urgent need to educate CRF patients regarding facts about the disease, medications, dietary habits, and various measures required to manage the condition and lead a normal life. This paper attempts to delineate the mechanisms that could result in cardiovascular and other complications among CRF patients undergoing dialysis.Entities:
Keywords: cardiovascular risk; chronic renal failure; dialysis; end stage renal disease; glomerular filtration rate; hypertension
Year: 2017 PMID: 29067226 PMCID: PMC5654453 DOI: 10.7759/cureus.1603
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Figure 1Diagrammatic Representation of a Dialyzer
NaHCO3: sodium bicarbonate; NaCl: sodium chloride
Figure 2Flow Chart Showing the Stages and the Role of Dialysis
Figure 3Flow Chart Showing the Consequences of Dialysis Associated with an Inflammation of the Kidney
IL-1: interleukin 1; T3: triiodothyronine; T4: tetraiodothyronine/thyroxine
Figure 4Flow Chart Showing Hypertension Related to Kidney Dysfunction and Its Effect on Various Metabolites
ADMA: asymmetric dimethyl arginine; HDL: high-density lipoproteins; NO: nitric oxide; apo A1: apolipoprotein A1